Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
14.4% rise in Humacyte's short interest in September, with 16.03 million shares sold short.
Humacyte, Inc. (NASDAQ: HUMA) experienced a 14.4% rise in short interest in September, totaling 16.03 million shares, with a short-interest ratio of 5.1 days.
Currently, 16.4% of its shares are sold short.
Brokerages have mostly assigned positive ratings, with a $15 price target from Benchmark.
CEO Laura E. Niklason sold 157,704 shares at $5.42 each.
Institutional investors hold 44.71% of Humacyte, which has a market cap of $691.88 million.
3 Articles
14,4% de aumento en el corto interés de Humacyte en septiembre, con 16.03 millones de acciones vendidas en corto.